Research Experience in the Program
Research Experience in the Program
In the research-intensive track, each fellow spends 24 months (6 months during the 1st year, 12 months during the 2nd year, and 6 months during the 3rd year) in a research experience that is supervised either by endocrine division faculty or by other members of the faculty at Case Western Reserve University School of Medicine. These two years of the fellowship are usually funded by an NIH Training Grant administered within Case Western Reserve University. This grant has a US residency requirement, and therefore, fellows pursuing this track must be either US citizens or permanent residents of the United States. Research projects and mentors are chosen during the first six months of fellowship with the assistance of the Training Program Director. Acceptable research projects range from basic science to clinical, patient-based research. Fellows often enter the program with prior research experience, but this is not required.
In the clinician-educator track, each fellow spends 15 months in research. This work can be basic or clinical, although it is expected that fellows in this track will more likely gravitate toward clinical research projects. This track has less restrictive funding sources and is, therefore, open to a broader pool of applicants.
During the research component of both tracks, clinic time is reduced to continuity clinics only, usually either a ½ day per week or 2 whole days per month within the UH Rainbow Babies and Children’s Hospital system. This enables the fellow to dedicate 80% of his or her time to the research project.
Research projects of recent fellows have included topics in basic science (genetics of pubertal timing; inflammatory pathways in diabetic retinopathy; effect of resveratrol on Glut-1 mediated glucose transport; role of regulatory T-cells in the pathophysiology of type 1 diabetes) and clinical endocrinology (assessment of carbohydrate and insulin-dosing knowledge among youth with type 1 diabetes; diabetes knowledge assessment in patients with cystic fibrosis related diabetes; association of asthma prevalence and vitamin D levels; assessment of dietary quality in children with type 1 diabetes).
Our fellows and faculty present their findings at oral and poster presentations every year in national meetings of major academic societies, including Pediatric Academic Societies, American Diabetes Association and The Endocrine Society.
A partial list of recent articles authored by faculty and fellows in the division of pediatric endocrinology:
Determinants of glycemic control in youth with type 2 diabetes at randomization in the TODAY study. Bacha F, Pyle L, Nadeau K, Cuttler L, Goland R, Haymond M, Levitsky L, Lynch J, Weinstock RS, White NH, Caprio S, Arslanian S; The TODAY Study Group. Pediatr. Diabetes. 2012 Feb 15. doi: 10.1111/j.1399-5448.2011.00841.x.
Idiopathic short stature: decision making in growth hormone use. Maheshwari N, Uli NK, Narasimhan S, Cuttler L. Indian J Pediatr. 2012 Feb; 79 (2): 238-243.
Overcoming burdens in the regulation of clinical research in children. Proceedings of a consensus conference, in historical context. Levine RJ, Genel M, Cuttler L, Becker DJ, Nieman L, Rosenfield RL. Int J Pediatr Endocrinol. 2011 Dec 30; 2011(1):19.
Assessing the value of treatments to increase height. Cuttler L, Rosenfield RL. N Engl J Med. 2011 Mar 31; 364 (13): 1274-1276.
Specialty drugs for the treatment of short stature in children – pros, cons and perspectives for the future. Koontz MB, Cutler L. US Endocrinology. 2010 Nov; 6: 78-83.
A national study of physician recommendations to initiate and discontinue growth hormone for short stature. Silvers JB, Marinova D, Mercer MB, Connors A, Cuttler L. Pediatrics. 2010 Sep; 126 (3): 468-476.
Deletion at chromosomal band Xp22.12-Xp22.13 involving PDHA1 in a patient with congenital lactic acidosis Singer BH, Iyer RK, Kerr DS, Ahmad A. Mol Genet Metab. 2010 Sep; 101 (1): 87-89.
The presence of GAD and IA-2 antibodies in youth with a type 2 diabetes phenotype: results from the TODAY study. Klingensmith GJ, Pyle L, Arslanian S, Copeland KC, Cuttler L, Kaufman F, Laffel L, Marcovina S, Tollefsen SE, Weinstock RS, Linder B; TODAY Study Group. Diabetes Care. 2010 Sep; 33 (9): 1970-5.
Growth hormone and health policy. Cuttler L, Silvers JB. J Clin Endocrinol Metab. 2010 Jul; 95 (7): 3149-3153.
Somatic mosaicism for PDHA1 mutation in a male with pyruvate dehydrogenase complex deficiency. Coughlin CR 2nd, Krantz ID, Schmitt ES, Zhang S, Wong LJ, Kerr DS, Ganesh J. Mol Genet Metab. 2010 Jul; 100 (3): 296-299.
Parent involvement is associated with early success in obesity treatment. Heinberg LJ, Kutchman EM, Berger NA, Lawhun SA, Cuttler L, Seabrook RC, Horwitz SM. Clin Pediatr (Phila). 2010 May; 49 (5): 457465.
Increased synthesis of leukotrienes in the mouse model of diabetic retinopathy. Talahalli R, Zarini S, Sheibani N, Murphy RC, Gubitosi-Klug RA. Invest Ophthalmol Vis Sci. 2010 Mar; 51 (3): 1699-1708.
Treatment of mitochondrial electron transport chain disorders: a review of clinical trials over the past decade. Kerr DS. Mol Genet Metab. 2010 Mar; 99 (3): 246-255.
Development and validation of a questionnaire to assess carbohydrate and insulin-dosing knowledge in youth with type 1 diabetes. Koontz MB, Cuttler L, Palmert MR, O'Riordan M, Borawski EA, McConnell J, Kern EO. Diabetes Care. 2010 Mar; 33 (3): 4574-62.
Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Seminara J, Tuchman M, Krivitzky L, Krischer J, Lee HS, Lemons C, Baumgartner M, Cederbaum S, Diaz GA, Feigenbaum A, Gallagher RC, Harding CO, Kerr DS, Lanpher B, Lee B, Lichter-Konecki U, McCandless SE, Merritt JL, Oster-Granite ML, Seashore MR, Stricker T, Summar M, Waisbren S, Yudkoff M, Batshaw ML. Mol Genet Metab. 2010;100 Suppl 1: S97-105.